vs
ANI PHARMACEUTICALS INC（ANIP）与AdvanSix Inc.（ASIX）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是ANI PHARMACEUTICALS INC的1.5倍（$359.9M vs $247.1M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs -0.8%，领先11.9%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 9.4%），AdvanSix Inc.自由现金流更多（$36.1M vs $29.1M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 3.4%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
ANIP vs ASIX — 直观对比
营收规模更大
ASIX
是对方的1.5倍
$247.1M
营收增速更快
ANIP
高出20.3%
9.4%
净利率更高
ANIP
高出11.9%
-0.8%
自由现金流更多
ASIX
多$7.0M
$29.1M
两年增速更快
ANIP
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $359.9M |
| 净利润 | $27.5M | $-2.8M |
| 毛利率 | — | 7.6% |
| 营业利润率 | 14.1% | -0.7% |
| 净利率 | 11.1% | -0.8% |
| 营收同比 | 29.6% | 9.4% |
| 净利润同比 | 367.5% | -892.9% |
| 每股收益（稀释后） | $1.14 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPASIX
| Q4 25 | $247.1M | $359.9M | ||
| Q3 25 | $227.8M | $374.5M | ||
| Q2 25 | $211.4M | $410.0M | ||
| Q1 25 | $197.1M | $377.8M | ||
| Q4 24 | $190.6M | $329.1M | ||
| Q3 24 | $148.3M | $398.2M | ||
| Q2 24 | $138.0M | $453.5M | ||
| Q1 24 | $137.4M | $336.8M |
净利润ANIPASIX
| Q4 25 | $27.5M | $-2.8M | ||
| Q3 25 | $26.6M | $-2.6M | ||
| Q2 25 | $8.5M | $31.4M | ||
| Q1 25 | $15.7M | $23.3M | ||
| Q4 24 | $-10.3M | $352.0K | ||
| Q3 24 | $-24.2M | $22.3M | ||
| Q2 24 | $-2.3M | $38.9M | ||
| Q1 24 | $18.2M | $-17.4M |
毛利率ANIPASIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 6.8% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 17.9% | ||
| Q1 24 | — | 0.9% |
营业利润率ANIPASIX
| Q4 25 | 14.1% | -0.7% | ||
| Q3 25 | 15.9% | -0.9% | ||
| Q2 25 | 6.6% | 7.7% | ||
| Q1 25 | 13.3% | 7.7% | ||
| Q4 24 | -2.3% | -3.9% | ||
| Q3 24 | -13.8% | 7.5% | ||
| Q2 24 | 3.7% | 11.5% | ||
| Q1 24 | 14.8% | -7.0% |
净利率ANIPASIX
| Q4 25 | 11.1% | -0.8% | ||
| Q3 25 | 11.7% | -0.7% | ||
| Q2 25 | 4.0% | 7.7% | ||
| Q1 25 | 8.0% | 6.2% | ||
| Q4 24 | -5.4% | 0.1% | ||
| Q3 24 | -16.3% | 5.6% | ||
| Q2 24 | -1.7% | 8.6% | ||
| Q1 24 | 13.2% | -5.2% |
每股收益（稀释后）ANIPASIX
| Q4 25 | $1.14 | $-0.11 | ||
| Q3 25 | $1.13 | $-0.10 | ||
| Q2 25 | $0.36 | $1.15 | ||
| Q1 25 | $0.69 | $0.86 | ||
| Q4 24 | $-0.45 | $0.02 | ||
| Q3 24 | $-1.27 | $0.82 | ||
| Q2 24 | $-0.14 | $1.43 | ||
| Q1 24 | $0.82 | $-0.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $19.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $815.2M |
| 总资产 | $1.4B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPASIX
| Q4 25 | $285.6M | $19.8M | ||
| Q3 25 | $262.6M | $23.7M | ||
| Q2 25 | $217.8M | $18.4M | ||
| Q1 25 | $149.8M | $8.3M | ||
| Q4 24 | $144.9M | $19.6M | ||
| Q3 24 | $145.0M | $17.3M | ||
| Q2 24 | $240.1M | $12.1M | ||
| Q1 24 | $228.6M | $20.6M |
股东权益ANIPASIX
| Q4 25 | $540.7M | $815.2M | ||
| Q3 25 | $505.8M | $818.2M | ||
| Q2 25 | $436.8M | $823.7M | ||
| Q1 25 | $418.6M | $794.4M | ||
| Q4 24 | $403.7M | $774.6M | ||
| Q3 24 | $405.9M | $766.4M | ||
| Q2 24 | $455.8M | $746.6M | ||
| Q1 24 | $452.0M | $713.2M |
总资产ANIPASIX
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.3B | $1.6B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.3B | $1.6B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $920.8M | $1.5B | ||
| Q1 24 | $914.5M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $63.7M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $36.1M |
| 自由现金流率自由现金流/营收 | 11.8% | 10.0% |
| 资本支出强度资本支出/营收 | 0.5% | 7.7% |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | $6.4M |
8季度趋势，按日历期对齐
经营现金流ANIPASIX
| Q4 25 | $30.4M | $63.7M | ||
| Q3 25 | $44.1M | $26.6M | ||
| Q2 25 | $75.8M | $21.1M | ||
| Q1 25 | $35.0M | $11.4M | ||
| Q4 24 | $15.9M | $64.2M | ||
| Q3 24 | $12.5M | $57.3M | ||
| Q2 24 | $17.4M | $50.2M | ||
| Q1 24 | $18.3M | $-36.2M |
自由现金流ANIPASIX
| Q4 25 | $29.1M | $36.1M | ||
| Q3 25 | $38.0M | $66.0K | ||
| Q2 25 | $71.8M | $-7.2M | ||
| Q1 25 | $32.5M | $-22.6M | ||
| Q4 24 | $13.5M | $29.8M | ||
| Q3 24 | $7.7M | $26.8M | ||
| Q2 24 | $13.0M | $16.7M | ||
| Q1 24 | $13.7M | $-71.6M |
自由现金流率ANIPASIX
| Q4 25 | 11.8% | 10.0% | ||
| Q3 25 | 16.7% | 0.0% | ||
| Q2 25 | 34.0% | -1.7% | ||
| Q1 25 | 16.5% | -6.0% | ||
| Q4 24 | 7.1% | 9.1% | ||
| Q3 24 | 5.2% | 6.7% | ||
| Q2 24 | 9.4% | 3.7% | ||
| Q1 24 | 10.0% | -21.3% |
资本支出强度ANIPASIX
| Q4 25 | 0.5% | 7.7% | ||
| Q3 25 | 2.7% | 7.1% | ||
| Q2 25 | 1.9% | 6.9% | ||
| Q1 25 | 1.3% | 9.0% | ||
| Q4 24 | 1.3% | 10.4% | ||
| Q3 24 | 3.2% | 7.7% | ||
| Q2 24 | 3.2% | 7.4% | ||
| Q1 24 | 3.3% | 10.5% |
现金转化率ANIPASIX
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 0.67× | ||
| Q1 25 | 2.23× | 0.49× | ||
| Q4 24 | — | 182.29× | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
